Genetic testing for breast cancer patients in Chinese communities
Screening of Genetic Susceptibility Genes for Breast Cancer Patients and Establishment of High-risk Populations in Chinese Communities
This study is trying to see if certain gene changes are more common in breast cancer survivors from eastern China to help understand their risk for the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Sex | All |
| Sponsor | Fudan University Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT04265937 on ClinicalTrials.gov |
What this trial studies
This community-based prospective study focuses on breast cancer patients in eastern China, aiming to identify genetic susceptibility by testing for mutations in BRCA1, BRCA2, PTEN, CHEK2, and PALB2 genes. The study will involve up to 5000 breast cancer survivors who will provide clinical and genetic information, as well as family history. The research will measure mutation rates and establish a prediction model for genetic mutations, using logistic regression and the Kin-Cohort method to assess cancer penetrance in mutation carriers.
Who should consider this trial
Good fit: Ideal candidates include breast cancer patients of any age, regardless of gender, who are willing to participate and provide informed consent.
Not a fit: Patients who are healthy or have other malignant tumors without breast cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of genetic risks for breast cancer, leading to better screening and prevention strategies.
How similar studies have performed: Other studies have shown success in identifying genetic mutations related to breast cancer, making this approach both relevant and promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * breast cancer patients of any age; * both male and female; * the subjects signed the informed consent to participate in the study and abide by the study procedure before being selected. Exclusion Criteria: * healthy people or other malignant tumor patients without breast cancer; * unable to interview the investigator and sign the informed consent due to any reason; * it is impossible to collect peripheral blood or oral mucosa samples for any reason.
Where this trial is running
Shanghai, Shanghai Municipality
- Zhen Hu — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Zhen Hu, MD
- Email: zhenhu@fudan.edu.cn
- Phone: 86 21 64175590
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.